{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T05:18:20Z","timestamp":1776748700884,"version":"3.51.2"},"reference-count":140,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.jinf.2008.02.006","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T00:20:12Z","timestamp":1206404412000},"page":"16-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy"],"prefix":"10.1016","volume":"57","author":[{"given":"Leonardo","family":"Calza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Pocaterra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2008.02.006_bib1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib2","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib3","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/S0140-6736(02)11672-2","article-title":"Protease inhibitors and cardiovascular outcomes in patients with HIV-1","volume":"360","author":"Holmberg","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib4","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa030218","article-title":"for the The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study\u00a0Group. Combination antiretroviral therapy and the risk of myocardial infarction","volume":"349","author":"Friis-M\u00f8ller","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00042560-200204150-00003","article-title":"Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy","volume":"29","author":"Koppel","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/01.aids.0000166087.08822.bc","article-title":"Cardiovascular disease in HIV-positive patients","volume":"19","author":"Kamin","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib7","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/00002030-200110190-00013","article-title":"Elevated blood pressure in subjects with lipodystrophy","volume":"15","author":"Sattler","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/00004872-200307000-00028","article-title":"Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome","volume":"21","author":"Gazzaruso","year":"2003","journal-title":"J Hypertens"},{"key":"10.1016\/j.jinf.2008.02.006_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s10096-003-1034-z","article-title":"Prevalence of hypertension in HIV-positive patients on highly active antiretroviral therapy (HAART) compared with HAART-na\u00efve and HIV-negative controls: results from a Norwegian study on 721 patients","volume":"22","author":"Bergersen","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib10","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh013","article-title":"Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients","volume":"53","author":"Calza","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2008.02.006_bib11","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1086\/521936","article-title":"Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools?","volume":"45","author":"Friis-M\u00f8ller","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib12","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/00002030-200107270-00008","article-title":"Clinical assessment of HIV-associated lipodystrophy in an ambulatory population","volume":"15","author":"Lichtenstein","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0924-8579(03)00115-8","article-title":"Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management","volume":"22","author":"Calza","year":"2003","journal-title":"Int J Antimicrob Ag"},{"key":"10.1016\/j.jinf.2008.02.006_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome. Risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","article-title":"Redistribution of body\u00a0fat in HIV-infected women undergoing combined antiretroviral therapy","volume":"13","author":"Gervasoni","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib19","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00042560-200208010-00010","article-title":"Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a\u00a0population-based cohort","volume":"30","author":"Heath","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib23","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib24","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.2337\/diabetes.50.6.1378","article-title":"The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance","volume":"50","author":"Caron","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.jinf.2008.02.006_bib25","doi-asserted-by":"crossref","first-page":"41325","DOI":"10.1074\/jbc.M006474200","article-title":"Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors","volume":"275","author":"Dowell","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jinf.2008.02.006_bib26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0166-3542(00)00102-9","article-title":"HIV protease inhibitors block adipogenesis and increase lipolysis in vitro","volume":"47","author":"Lenhard","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jinf.2008.02.006_bib27","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1097\/00002030-200311210-00005","article-title":"Some HIV protease inhibitors alter lamin A\/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation","volume":"17","author":"Caron","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib28","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1293.2004.00178.x","article-title":"Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors","volume":"5","author":"Reiss","year":"2004","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","article-title":"Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib30","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1053\/meta.2002.34704","article-title":"Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy","volume":"51","author":"Hadigan","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jinf.2008.02.006_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00002030-200201040-00003","article-title":"Effects of antiretroviral drug combinations on the differentiation of adipocytes","volume":"16","author":"Roche","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib32","article-title":"Effects of transgenic expression of HIV-1 viral protein R (Vpr) on lipid and energy metabolism in mice","author":"Balasubramanyam","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jinf.2008.02.006_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1152\/physrev.1994.74.4.761","article-title":"Regional adiposity and morbidity","volume":"74","author":"Kissebah","year":"1994","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jinf.2008.02.006_bib34","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1161\/01.ATV.10.4.493","article-title":"\u201cPortal\u201d adipose tissue as a generator of risk factors for cardiovascular disease and diabetes","volume":"10","author":"Bjorntorp","year":"1990","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.jinf.2008.02.006_bib35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1055\/s-2001-17907","article-title":"Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women","volume":"33","author":"Mertens","year":"2001","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.jinf.2008.02.006_bib36","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/368185","article-title":"Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution","volume":"36","author":"Hadigan","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","article-title":"Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study","volume":"17","author":"Friis-M\u00f8ller","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib38","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1001\/archinte.160.13.2050","article-title":"Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study","volume":"160","author":"Tsiodras","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib39","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2008.02.006_bib40","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00002030-200001070-00006","article-title":"Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects","volume":"14","author":"Purnell","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00002030-200403050-00008","article-title":"The metabolic effects of lopinavir\/ritonavir in HIV-negative men","volume":"18","author":"Lee","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00126334-200301010-00004","article-title":"Results of a phase 2 clinical trial at 48weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects","volume":"32","author":"Sanne","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib43","unstructured":"Parker RA, Wang S, Mulvey R, et\u00a0al. Differential effects of HIV protease inhibitors on proteosome, gene expression, and lipogenesis provide a mechanism for PI-associated dyslipidaemia and atazanavir's favourable lipid profile. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 2004."},{"key":"10.1016\/j.jinf.2008.02.006_bib44","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/nm1201-1327","article-title":"HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia","volume":"7","author":"Liang","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib45","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1194\/jlr.M200129-JLR200","article-title":"The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice","volume":"43","author":"Riddle","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jinf.2008.02.006_bib46","doi-asserted-by":"crossref","first-page":"37514","DOI":"10.1074\/jbc.M104557200","article-title":"HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus","volume":"276","author":"Riddle","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jinf.2008.02.006_bib47","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/00002030-200109070-00006","article-title":"Mitochondrial involvement in antiretroviral therapy-related lipodystrophy","volume":"15","author":"Zaera","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00041433-200402000-00011","article-title":"Pathophysiology of dyslipidaemia and increased cardiovascular risk in HIV lipodystrophy: a model of \u201csystemic steatosis\u201d","volume":"15","author":"Balasubramanyam","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jinf.2008.02.006_bib49","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/00002030-200112070-00007","article-title":"An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride\/low HDL levels in treated HIV patients","volume":"15","author":"Fauvel","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib50","unstructured":"Brown T, Cole SR, Li X, et\u00a0al. Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, USA, 2004."},{"key":"10.1016\/j.jinf.2008.02.006_bib51","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1172\/JCI200215626","article-title":"Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy","volume":"110","author":"Behrens","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jinf.2008.02.006_bib52","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1097\/00002030-200111090-00004","article-title":"Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways","volume":"15","author":"Van Der Valk","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib53","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/eje.1.01835","article-title":"Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells","volume":"152","author":"Haugaard","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jinf.2008.02.006_bib54","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00002030-200204120-00005","article-title":"Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations","volume":"16","author":"Murata","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib55","doi-asserted-by":"crossref","first-page":"20251","DOI":"10.1074\/jbc.C000228200","article-title":"The mechanism of insulin resistance caused by HIV protease inhibitor therapy","volume":"275","author":"Murata","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jinf.2008.02.006_bib56","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/496990","article-title":"Insulin resistance among HIV-infected patients: unraveling the mechanism","volume":"41","author":"Hadigan","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/meta.2002.29999","article-title":"Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution","volume":"51","author":"Meininger","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jinf.2008.02.006_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1161\/01.CIR.0000108926.04022.0C","article-title":"Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey","volume":"109","author":"Ninomiya","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jinf.2008.02.006_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: An American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jinf.2008.02.006_bib60","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2337\/diacare.25.7.1253","article-title":"Prevalence of metabolic syndrome among HIV patients","volume":"25","author":"Gazzaruso","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jinf.2008.02.006_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/diacare.28.1.132","article-title":"Metabolic syndrome among HIV-infected patients","volume":"28","author":"Jeric\u00f2","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jinf.2008.02.006_bib62","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1097\/QAD.0b013e3282efad32","article-title":"Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection","volume":"21","author":"Wand","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib63","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1086\/516616","article-title":"Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV","volume":"44","author":"Mangili","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib64","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(04)00971-5","article-title":"HIV infection, HAART, and endothelial adhesion molecules: current perspectives","volume":"4","author":"De Gaetano Donati","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib65","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/MOL.0b013e3282ef604f","article-title":"How HIV protease inhibitors promote atherosclerotic lesion formation","volume":"18","author":"Thomas","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.jinf.2008.02.006_bib66","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/00005344-199806000-00009","article-title":"Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release","volume":"31","author":"Stefano","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.jinf.2008.02.006_bib67","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/labinvest.3780418","article-title":"HIV-1 envelope glycoprotein 120 increases intercellular adhesion molecule-1 expression by human endothelial cells","volume":"82","author":"Ren","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.jinf.2008.02.006_bib68","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1161\/01.CIR.96.12.4219","article-title":"Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study","volume":"96","author":"Hwang","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jinf.2008.02.006_bib69","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2337\/diabetes.49.3.485","article-title":"Increased levels of soluble vascular cell adhesion molecule I are associated with risk of cardiovascular mortality in type 2 diabetes: the Hoorn study","volume":"49","author":"Jager","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.jinf.2008.02.006_bib70","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-2494(97)82482-0","article-title":"Circulating cell adhesion molecules in HIV-1-infected patients as indicator markers for AIDS progression","volume":"148","author":"Galea","year":"1999","journal-title":"Res Immunol"},{"key":"10.1016\/j.jinf.2008.02.006_bib71","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1086\/338572","article-title":"Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1","volume":"185","author":"Wolf","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib72","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/00002030-200303280-00020","article-title":"Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy","volume":"17","author":"De Gaetano Donati","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib73","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.ATV.0000034707.40046.02","article-title":"HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells","volume":"22","author":"Zhong","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jinf.2008.02.006_bib74","unstructured":"Dub\u00e9 MP, Vanderluitgaren JM, Leffler CM, Baron AD, Steinberg HO. Effect of indinavir (IND) monotherapy on endothelial function in men without HIV infection. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 2002."},{"key":"10.1016\/j.jinf.2008.02.006_bib75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00126334-200302010-00014","article-title":"C-reactive protein is an independent predictor of mortality in women with HIV-1 infection","volume":"32","author":"Feldman","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/01.ATV.0000048856.22331.50","article-title":"Association of hypoadiponectinemia with coronary artery disease in men","volume":"23","author":"Kumada","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jinf.2008.02.006_bib77","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/en.2003-1140","article-title":"Adiponectin ameliorates dyslipidaemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice","volume":"145","author":"Xu","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.jinf.2008.02.006_bib78","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00002030-200404300-00010","article-title":"Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study","volume":"18","author":"Maggi","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.atherosclerosis.2006.05.026","article-title":"Rapid progression of carotid lesions in HAART-treated HIV-1 patients","volume":"192","author":"Maggi","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jinf.2008.02.006_bib80","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.mca.0000236292.86930.e3","article-title":"An ultrasound-based comparative study on carotid plaques in HIV-positive patients vs. atherosclerotic and arteritis patients: atherosclerotic of inflammatory lesions?","volume":"18","author":"Maggi","year":"2007","journal-title":"Coronary Artery Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib81","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1161\/STROKEAHA.106.479030","article-title":"The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection","volume":"38","author":"Coll","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.jinf.2008.02.006_bib82","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1161\/01.STR.0000204037.26797.7f","article-title":"Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy","volume":"37","author":"Jeric\u00f2","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.jinf.2008.02.006_bib83","article-title":"Premature atherosclerosis in HIV-positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)","author":"De Saint Martin","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jinf.2008.02.006_bib84","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jinf.2008.02.006_bib85","article-title":"Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis","author":"Lorenz","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jinf.2008.02.006_bib86","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/QAD.0b013e328133f29c","article-title":"Increased carotid intima-media thickness and cardiac biomarkers in HIV infected children","volume":"21","author":"McComsey","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib87","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00002030-200102160-00005","article-title":"Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy","volume":"15","author":"Depairon","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib88","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1161\/01.CIR.0000124480.32233.8A","article-title":"Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection","volume":"109","author":"Hsue","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jinf.2008.02.006_bib89","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/01.aids.0000171406.53737.f9","article-title":"Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure","volume":"19","author":"Currier","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib90","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/509575","article-title":"Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score","volume":"43","author":"Mangili","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib91","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1475-097X.2007.00737.x","article-title":"Carotid intima-media thickness in HIV patients treated with antiretroviral therapy","volume":"27","author":"Lebech","year":"2007","journal-title":"Clin Physiol Funct Imaging"},{"key":"10.1016\/j.jinf.2008.02.006_bib92","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/qjmed\/hcg145","article-title":"Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk?","volume":"96","author":"Nolan","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.jinf.2008.02.006_bib93","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/00002030-200404300-00012","article-title":"Arterial stiffness and endothelial dysfunction in HIV-infected children","volume":"18","author":"Bonnet","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib94","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11906-000-0031-1","article-title":"Hypertension in the HIV-infected patient","volume":"2","author":"Aoun","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.jinf.2008.02.006_bib95","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0140-6736(05)79053-X","article-title":"Severe premature coronary artery disease with protease inhibitors","volume":"351","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib96","first-page":"351","article-title":"Vascular complications associated with use of HIV protease inhibitors","volume":"1998","author":"Vittecoq","year":"1959","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib97","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1097\/00002030-200012010-00021","article-title":"Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapy","volume":"14","author":"Friedl","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib98","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.qai.0000147525.26746.07","article-title":"Managing cardiovascular risk in patients with HIV infection","volume":"38","author":"Stein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib99","first-page":"329","article-title":"Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study","volume":"5","author":"Rickerts","year":"2000","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jinf.2008.02.006_bib100","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/00126334-200208150-00002","article-title":"Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?","volume":"30","author":"Klein","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib101","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00126334-200308010-00012","article-title":"Coronary heart disease in HIV-infected individuals","volume":"33","author":"Currier","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib102","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/00002030-200311210-00010","article-title":"Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men","volume":"17","author":"Mary-Krause","year":"2003","journal-title":"AIDS"},{"issue":"Suppl. 1","key":"10.1016\/j.jinf.2008.02.006_bib103","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/00002030-200304001-00010","article-title":"Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era","volume":"17","author":"Vittecoq","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib104","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa062744","article-title":"Class of antiretroviral drugs and the risk of myocardial infarction","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib105","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1086\/518285","article-title":"Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study","volume":"44","author":"Obel","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib106","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1468-1293.2005.00265.x","article-title":"Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients","volume":"6","author":"Iloeje","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib107","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1086\/521935","article-title":"Ten-year predicted coronary heart disease risk in HIV-infected men and women","volume":"45","author":"Kaplan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib108","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib109","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.410140404","article-title":"Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients","volume":"14","author":"Snider","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jinf.2008.02.006_bib110","first-page":"41","article-title":"Central nervous system dysfunction in acquired immunodeficiency syndrome","volume":"1","author":"Levy","year":"1988","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000068828","article-title":"Ischaemic cerebrovascular events in HIV infection. A cohort study","volume":"15","author":"Evers","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib112","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1097\/00002030-200409030-00010","article-title":"Cardio- and cerebrovascular events in HIV-infected persons","volume":"18","author":"D'Arminio Monforte","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib113","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dub\u00e9","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib114","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","year":"2001","journal-title":"JAMA"},{"issue":"4A","key":"10.1016\/j.jinf.2008.02.006_bib115","doi-asserted-by":"crossref","first-page":"53E","DOI":"10.1016\/j.amjcard.2005.06.006","article-title":"Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options","volume":"96","author":"Stone","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jinf.2008.02.006_bib116","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/00002030-200110190-00021","article-title":"Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy","volume":"15","author":"Jones","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib117","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1152\/jappl.2001.90.1.133","article-title":"Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy","volume":"90","author":"Yarasheski","year":"2001","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.jinf.2008.02.006_bib118","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0021-9150(02)00016-3","article-title":"Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: \u201ca call for cardiovascular prevention\u201d","volume":"163","author":"Acevedo","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jinf.2008.02.006_bib119","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJMoa021589","article-title":"Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection","volume":"349","author":"Martinez","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib120","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/00002030-200311210-00007","article-title":"Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients","volume":"17","author":"Bucher","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib121","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-5-2","article-title":"Substituting abacavir for hyperlipidaemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment","volume":"5","author":"Keiser","year":"2005","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib122","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib123","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2008.02.006_bib124","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1086\/517497","article-title":"Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results","volume":"44","author":"Gatell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2008.02.006_bib125","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00002030-200304110-00010","article-title":"Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"17","author":"Calza","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib126","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1468-1293.2004.00200.x","article-title":"Fibrates or statins and\u00a0lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999\u20132001","volume":"5","author":"Bonnet","year":"2004","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib127","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.aids.0000174451.78497.8f","article-title":"Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1468-1293.2007.00480.x","article-title":"The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review","volume":"8","author":"McGoldrick","year":"2007","journal-title":"HIV Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib129","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.clinthera.2004.09.005","article-title":"Rosuvastatin in the management of hyperlipidemia","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.jinf.2008.02.006_bib130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/01.aids.0000174458.86121.43","article-title":"Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study","volume":"19","author":"Calza","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.jinf.2008.02.006_bib131","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1177\/135965350701200711","article-title":"Pharmacokinetics and pharmacodynamics of combined use of lopinavir-ritonavir and rosuvastatin in HIV-infected patients","volume":"12","author":"van der Lee","year":"2007","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2008.02.006_bib132","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s15010-001-2052-3","article-title":"Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART","volume":"30","author":"Calza","year":"2002","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2008.02.006_bib133","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/00126334-200407010-00017","article-title":"Polyunsaturated ethyl esters of n-3 fatty acids in HIV-infected patients with moderate hypertriglyceridemia: comparison with dietary and lifestyle changes, and fibrate therapy","volume":"36","author":"Manfredi","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jinf.2008.02.006_bib134","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2008.02.006_bib135","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1210\/jc.2002-020709","article-title":"Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance","volume":"87","author":"Hadigan","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jinf.2008.02.006_bib136","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-143-5-200509060-00009","article-title":"Comparison of rosiglitazone and metformin for treating HIV lipodystrophy","volume":"143","author":"Van Vijk","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2008.02.006_bib137","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/135965350300800303","article-title":"Rosiglitazone in the treatment of HAART-associated lipodystrophy- a randomized double-blind placebo-controlled study","volume":"8","author":"Sutinen","year":"2003","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jinf.2008.02.006_bib138","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0140-6736(04)15489-5","article-title":"No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial","volume":"363","author":"Carr","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2008.02.006_bib139","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/jac\/dki234","article-title":"Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients","volume":"56","author":"Oette","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2008.02.006_bib140","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/14656566.3.5.529","article-title":"Thiazolidinediones in the treatment of type 2 diabetes","volume":"3","author":"Pittas","year":"2002","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445308000881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445308000881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:33:16Z","timestamp":1758987196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445308000881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0163445308000881"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2008.02.006","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2008.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}